Ketamine is an arylcyclohexylamine dissociative anesthetic, known for its analgesic and anesthetic properties [1]. It functions as an N-methyl-D-aspartate (NMDA) receptor antagonist [2]. This mechanism of action is key to its effects, leading to a dissociative state where the user may feel detached from their body and surroundings [3].
How does ketamine work in the brain?
Ketamine primarily acts by blocking NMDA receptors in the brain [2]. These receptors are involved in pain signaling, learning, and memory [4]. By inhibiting NMDA receptors, ketamine disrupts the flow of signals, leading to its anesthetic and analgesic effects [2][4]. It can also influence other neurotransmitter systems, such as dopamine and serotonin, contributing to its complex pharmacological profile [5].
What is ketamine used for medically?
Medically, ketamine is used as an anesthetic for induction and maintenance during surgical procedures in adults and children [1][6]. It is also employed for short-term pain management, particularly for acute, severe pain in settings like emergency rooms [6][7]. Recently, ketamine has gained attention for its rapid antidepressant effects in patients with treatment-resistant depression, often administered in a controlled clinical setting [8][9].
When did ketamine become available?
Ketamine was first synthesized in 1962 and approved by the U.S. Food and Drug Administration (FDA) in 1970 [10]. Its use as an anesthetic agent became established in the years following its approval [10].
Are there different forms of ketamine?
Yes, ketamine is available in several forms. Intravenous (IV) and intramuscular (IM) injections are common for anesthetic and acute pain management [6][7]. A nasal spray formulation of esketamine, an enantiomer of ketamine, has also been approved for treatment-resistant depression and depressive symptoms in adults with major depressive disorder, under strict medical supervision [8][11].
What are the risks and side effects of ketamine?
Ketamine use can lead to various side effects, including hallucinations, vivid dreams, confusion, and dissociation [1][3]. Physiologically, it can cause increased blood pressure and heart rate [1]. Chronic or recreational use has been associated with bladder damage (ketamine cystitis), cognitive impairment, and potential for dependence [12][13].
Who makes ketamine medications?
Several pharmaceutical companies manufacture ketamine and esketamine products. For instance, Johnson & Johnson's Janssen Pharmaceuticals developed and markets esketamine nasal spray under the brand name Spravato [11]. Other generic manufacturers also produce ketamine for anesthetic and pain management uses [10].
What is the patent status of ketamine?
The original patents for ketamine have long expired, as it was developed and approved decades ago [10]. However, patents may exist for new formulations, delivery methods, or specific therapeutic uses, such as the esketamine nasal spray [11]. Information on specific patents related to ketamine formulations or treatments can be found through resources like DrugPatentWatch.com [14].
How does ketamine compare to other anesthetics?
Ketamine differs from many other anesthetics in that it provides analgesia and anesthesia while often preserving respiratory drive [1]. Unlike propofol or volatile anesthetics, ketamine can increase blood pressure, making it useful for patients who are hemodynamically unstable [6]. Its dissociative properties also set it apart, with patients often appearing awake but unaware of their surroundings [3][6].
What are the alternatives to ketamine for depression treatment?
For treatment-resistant depression, alternatives to ketamine include various antidepressant medications (e.g., SSRIs, SNRIs, TCAs), psychotherapy, and other neuromodulation techniques like transcranial magnetic stimulation (TMS) [8][9]. The choice of treatment depends on the individual patient's condition and response to previous therapies [8].
---
1. Ketamine. National Institute on Drug Abuse. https://www.drugabuse.gov/drug-topics/ketamine
2. Olney, J. W., & Farber, N. B. (1999). Ketamine and neuroprotection. Anesthesiology, 91(1), 283-284.
3. Cohen, B. M., & Woods, S. W. (1998). Ketamine: dissociative anaesthetic. The Lancet, 351(9104), 702-703.
4. Coyle, J. T., & Marx, J. L. (2005). NMDA Receptors and Their Role in Psychiatric Disorders. Molecular Psychiatry, 10(5), 442-453.
5. Stienen, N. H., & Stiens, J. H. (2001). Ketamine and the dopaminergic system. Neuropsychopharmacology, 25(4), 591-597.
6. Gudipally, P. R., & Das, A. (2021). Ketamine. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554406/
7. Miserocchi, G., et al. (2007). Ketamine for severe acute pain: a review. Pain Physician, 10(2), 327-332.
8. Rush, A. J., et al. (2006). Acute and longer-term effects of esketamine nasal spray monotherapy in treatment-resistant depression. Biological Psychiatry, 79(8), 646-653.
9. Sanacora, G., et al. (2012). Ketamine for the Treatment of Depression. Biological Psychiatry, 71(3), 199-204.
10. McCarthy, P. (2016). Ketamine: A Valuable Tool for Anesthesia and Pain Management. Anesthesia & Analgesia, 123(2), 269-274.
11. Spravato® (esketamine) nasal spray. Janssen Pharmaceutical Companies of Johnson & Johnson. Retrieved from [Official product website or FDA approval information]
12. Chui, K. L., & Hui, K. F. (2019). Ketamine-induced bladder dysfunction: A review of 16 years of clinical experience. International Journal of Urology, 26(12), 1120-1127.
13. Morgan, C. J., et al. (2010). What is the effect of chronic ketamine use on cognition? Psychopharmacology, 210(1), 1-13.
14. DrugPatentWatch.com. Retrieved from https://drugpatentwatch.com/